AMAG rises as Feraheme prospects broaden
This article was originally published in Scrip
Executive Summary
AMAG Pharmaceuticals' attempts to broaden the label of its iron deficiency product Feraheme have made an encouraging start, prompting a short-lived 10% leap in its share price in after-hours trading.